BUSINESS

• Astellas Eyes 1 Trillion Yen Peak Sales with 6 Late-Stage Assets: Biz Plan
  May 23, 2018

• Astellas to Shed 600 Jobs to Revamp Japan Operations
  May 23, 2018

• Hemlibra, MSD/Astellas’ DPP-4/SGLT2 Combo Hit Japan Market
  May 23, 2018

• Top 4 Wholesalers Report Unusually Low Growth in Drug Wholesale Business for 2nd Year after Price Revision
  May 23, 2018

• JCR’s Sakigake-Designated Hunter Syndrome Treatment to Enter PII/III in 1st Half of FY2018
  May 23, 2018

• Janssen Files Triple-Combo for HIV Treatment in Japan
  May 23, 2018

• Takeda Divests China JV Techpool
  May 22, 2018

• Kyowa Kirin to Use Surrogate Endpoint in PIII Trial of Sakigake CKD Treatment; Application Could Come as Early as 2022
  May 22, 2018

• AZ Files Forxiga for Expanded Use in Type 1 Diabetes in Japan
  May 22, 2018

• Ethical Drug Sales Up 0.2% in FY2017: Crecon Report
  May 21, 2018

• Dustin Haines Named as President of ViiV Healthcare Japan
  May 21, 2018

• Growject to Enter PIII Study for SHOX Deficiency: JCR
  May 21, 2018

• Kyowa Kirin’s Burosumab Hits Primary Endpoint in Multinational PIII Study in XLH Children including Japan
  May 21, 2018

• Nobelpharma Becomes Medipal’s Equity Method Affiliate
  May 21, 2018

• Talion Authorized Generics Rack Up 1.5 Billion Yen in Single Month
  May 18, 2018

• Fujifilm’s Cancer Peptide Vaccine Flops in Japan PIII
  May 18, 2018

• Sawai Seeks Strategical Alliance, Intra-Industry Network under New Midterm Biz Plan
  May 18, 2018

• 10 Major Japan Drug Makers’ Sales Up 3.3%, but Decline Expected for FY2018 on Price Revision
  May 18, 2018

• Alecensa Approved for 1st-Line Treatment of NSCLC in Taiwan: Chugai
  May 17, 2018

• Daiichi Sankyo, Canadian Biotech Expand Joint Research on Bispecific Antibodies
  May 16, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 385
• 386
• 387
• 388
• 389
• 390
• 391
• 392
• 393
• …
• Next ›
• 最終 »